Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
暂无分享,去创建一个
T. Powles | J. Rosenberg | T. Kojima | H. Azuma | J. Yonese | N. Matsubara | H. Matsumoto | D. Petrylak | M. Matsangou | Mary S. Campbell | Chunzhang Wu | Mayumi Yamashiro